Skip to content
Credit reportVerdict and grounds
Made on 19-11-2026 at 11:22
Reference CK-1017566820-20261119

WOLFS PHARMA

ActivePrivate limited company1017.566.820Rue Jean-Hermesse 45, 4020 Liège
Retail sale of pharmaceutical products (NACE 47730) · founded in 2024 · 3 employees on 31-12-2025 · one director · accounts in the micro format

Sources: the KBO register on 19-11-2026; the National Bank, 2025 annual accounts filed on 01-06-2026; the Belgian Official Gazette, latest deed of 20-12-2024.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,303 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€131,915
Net result
€30,540
Equity
€40,540
Cash
€65,828

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, WOLFS PHARMA closed with a net profit of €30,540.Annual accounts 2025 page 2
  2. Equity stands at €40,540, or 8.0% of the balance sheet total of €509,540.Annual accounts 2025 page 2
  3. The 2025 accounts reached the National Bank 60 days before the end of the term.National Bank, filing of 01-06-2026 page 4

Representation

Checked did not find the signing rule in the deeds it read.

Ownership

The accounts in the micro format list no shareholders. holds 100 shares.

Deed of 20-12-2024

WOLFS PHARMA · 1017.566.820 · credit report of 19-11-2026Page 1 of 5
WOLFS PHARMA1017.566.820 · report of 19-11-2026

Financial situation

Annual accounts 2025, as filed with the National Bank

Gross margin and net resultin euro

2025131,915202530,540
gross marginnet result

Equity and debtsin euro

202540,540468,999
equitydebts

Cashin euro

202565,828
on the balance sheet date
Financial year2025Trend
Results
Gross margin€131,915
Operating result€45,080
Net result€30,540
Balance sheet at the closing date
Equity€40,540
Debts€468,999
Debts due after more than one year€158,271
Debts due within one year€310,195
Cash€65,828
Balance sheet total€509,540
Operations
Employees in full-time equivalents1.5
Ratios
Solvency8.0%
Liquidity0.71

Source: Annual accounts 2025, micro format, filed on 01-06-2026 (2026-00130748).

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

WOLFS PHARMA states no turnover; the micro format does not require it.

WOLFS PHARMA · 1017.566.820 · credit report of 19-11-2026Page 2 of 5
WOLFS PHARMA1017.566.820 · report of 19-11-2026

Board, signature and ownership

Position on 19-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

Checked did not find the signing rule in the deeds it read.

Board

one director in office
Sole directorsince 18-12-2024
term without a fixed enddeed of 20-12-2024

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. holds 100 shares.

Deed of 20-12-2024

WOLFS PHARMA · 1017.566.820 · credit report of 19-11-2026Page 3 of 5
WOLFS PHARMA1017.566.820 · report of 19-11-2026

Events and comparison

The last 24 months, newest first

Annual accounts 2025 filed, 60 days before the deadline.

NBB filing

Registered in the Peppol Directory. Reachable for e-invoices through 0208:1017566820.

First establishment. Rue Jean-Hermesse 45, Liège.

Incorporation. Founding capital of €10,000, 100 shares. Founded by (comparant). appointed as sole director. Published on 20-12-2024.

Gazette, deed 24453762

Comparable companies, two years later

In July 2024, 320 companies had the same profile as WOLFS PHARMA has now: micro, under 2 years old, solvency under 10% and a profit of 5% of the balance sheet or more. Two years later 96.6% were still trading, 2.5% had stopped another way and 0.9% had gone bankrupt.

still trading 96.6% stopped another way 2.5% bankrupt 0.9%

In 2025, WOLFS PHARMA had a higher net result than 81% of the 25,359 companies in the retail trade sector (NACE 47).

Other findings

Peppol

Reachable for e-invoices since 05-11-2025, under 0208:1017566820.

Sanctions lists

Staff

3 employees on 31-12-2025, 1.5 full-time equivalents on average over the year.

WOLFS PHARMA · 1017.566.820 · credit report of 19-11-2026Page 4 of 5
WOLFS PHARMA1017.566.820 · report of 19-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units19-11-2026KBO 1017.566.820
National Bank of BelgiumAnnual accounts 2025, micro format01-06-20262026-00130748
Peppol DirectoryRegistration for e-invoices05-11-20250208:1017566820
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name16-11-2026no match
CheckedChecked score, bankruptcy probability, credit, comparable companies18-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 18-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

WOLFS PHARMA · 1017.566.820 · credit report of 19-11-2026Page 5 of 5